Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials

0
608
Glenmark Pharmaceuticals

India/USA; January 10, 2023 – Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex®1 Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.

Commenting on the launch, Vijay Raghavan, Senior Vice President, Business Development Portfolio, Product Launch & Strategy said, “We are very pleased to bring to market a lower cost alternative to Bumex® Injection, 0.25 mg/mL. This launch of Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials affirms our commitment to Glenmark’s continued focus on institutional business.”

According to IQVIATM sales data for the 12-month period ending November 2022, the Bumex® Injection, 0.25 mg/mL market2 achieved annual sales of approximately $16.5 million*.

Glenmark’s current portfolio consists of 179 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.